文献速递腹部介入CT

局部晚期及复发性胰腺癌经皮不可逆电穿孔治疗(PANFIRE-2):一项多中心、前瞻性、单臂、II期研究

Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
PubMed 文献 · Radiology · 2019-11-05

这项前瞻性II期单臂多中心研究纳入50例局部晚期胰腺癌或术后局部复发患者,行CT引导经皮不可逆电穿孔(IRE)治疗。局部晚期胰腺癌组中位总生存期自诊断起为17个月,超过预设目标11.6个月和14.9个月;复发组自复发诊断起为16个月。肿瘤体积≥37 cm3、IRE前CA 19-9≥2000 U/mL及IRE后3个月CA 19-9下降≤50%为生存较差的预测因素。

要点

  • CT引导经皮IRE治疗后局部晚期胰腺癌自诊断起中位OS为17个月,超过预设目标。
  • 肿瘤体积≥37 cm3、IRE前CA 19-9≥2000 U/mL、IRE后3个月CA 19-9下降≤50%提示生存较差。
  • 50例中29例(58%)发生并发症,14例次轻微、21例次严重;2例于IRE后90天内死亡,其中1例可能与IRE相关。

核心结论

  • CT引导经皮IRE治疗局部晚期胰腺癌患者自诊断起中位OS为17个月,局部复发患者自复发诊断起为16个月,均超过预设目标中位OS。

研究设计与样本

  • 多中心、前瞻性、单臂、II期研究,2012年12月至2017年9月纳入50例局部晚期胰腺癌(40例)或术后局部复发(10例)患者,行CT引导经皮IRE治疗(ClinicalTrials.gov标识NCT01939665)。
  • 主要终点为自诊断起的中位总生存期,局部晚期胰腺癌预设目标中位OS为未接受诱导化疗或接受吉西他滨为基础诱导化疗者11.6个月、接受FOLFIRINOX诱导化疗者14.9个月。

诊断标准与关键数值

  • 局部晚期胰腺癌组自诊断起中位OS为17个月(95%CI:15个月,19个月),自IRE起为10个月(95%CI:8个月,11个月)。
  • 局部晚期胰腺癌组中18例接受无治疗或吉西他滨为基础诱导化疗、22例接受FOLFIRINOX,两组自诊断起中位OS均为17个月(95%CI分别为7个月,28个月和15个月,18个月;P=.26)。
  • 术后局部复发组自复发诊断起中位OS为16个月(95%CI:11个月,22个月),自IRE起为9个月(95%CI:2个月,16个月)。
  • 肿瘤体积≥37 cm3(HR 2.9;P=.02)、IRE前CA 19-9≥2000 U/mL(HR 12.1;P=.001)、IRE后3个月CA 19-9下降≤50%(HR 3.1;P=.01)为生存较差的预测因素。

临床应用与阅片要点

  • IRE后50例中23例(46%)出现局部复发。
  • 50例中29例(58%)发生并发症,共14例次轻微并发症和21例次严重并发症;2例于IRE后90天内死亡,其中1例死亡可能与IRE相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Patients with locally advanced pancreatic cancer have a dismal prognosis, with a median overall survival (OS) of 12-14 months with systemic therapies. Irreversible electroporation (IRE), a nonthermal ablative technique, may prolong survival of patients with locally advanced pancreatic cancer. Purpose To investigate the safety and efficacy of percutaneous IRE for locally advanced pancreatic cancer and locally recurring pancreatic cancer in a prospective phase II trial. Materials and Methods Between December 2012 and September 2017, participants with locally advanced pancreatic cancer or postresection local recurrence were prospectively treated with percutaneous CT-guided IRE (ClinicalTrials.gov identifier: NCT01939665). The primary end point was median OS from diagnosis. The target median OS was 11.6 months for participants receiving no induction chemotherapy or gemcitabine-based induction chemotherapy and 14.9 months for those receiving induction 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Results Fifty participants (25 men and 25 women; median age, 61 years [interquartile range, 56-69 years]; 40 with locally advanced pancreatic cancer and 10 with local recurrence) were included. Median OS measured by using the Kaplan-Meier method was 17 months from diagnosis of locally advanced pancreatic cancer (95% confidence interval [CI]: 15 months, 19 months) and 10 months from IRE (95% CI: 8 months, 11 months). In the locally advanced pancreatic cancer group, 18 participants received no therapy or gemcitabine-based induction chemotherapy and 22 received FOLFIRINOX. The median OS from diagnosis was 17 months for both groups (95% CI: 7 months, 28 months and 15 months, 18 months, respectively; P = .26). For participants with postresection local recurrence, the median OS was 16 months from diagnosis of recurrence (95% CI: 11 months, 22 months) and 9 months from IRE (95% CI: 2 months, 16 months). After IRE, local recurrence developed in 23 of the 50 participants (46%). Tumor volume of 37 cm3 or greater (hazard ratio [HR], 2.9; P = .02), pre-IRE carbohydrate antigen 19-9 (CA 19-9) level of 2000 U/mL or greater (HR, 12.1; P = .001), and decrease in CA 19-9 level of 50% or less 3 months after IRE (HR, 3.1; P = .01) were predictors of worse survival. Fourteen minor and 21 major complications occurred in 29 of the 50 participants (58%). Two participants died less than 90 days after IRE; one of these deaths was likely related to IRE. Conclusion The target median overall survival with CT-guided percutaneous irreversible electroporation was exceeded in participants with locally advanced pancreatic cancer (17 months) and those with local recurrence (16 months). © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Goldberg in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ruarus AH, Vroomen LGPH, Geboers B, et al. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Radiology. 2019. PMID: 31687922. doi:10.1148/radiol.2019191109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。